ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Givaudan SA (PK)

Givaudan SA (PK) (GVDNY)

86.80
-0.05
(-0.06%)
Closed 05 January 8:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
86.80
Bid
85.60
Offer
88.26
Volume
33,998
85.80 Day's Range 87.11
75.5455 52 Week Range 110.315
Market Cap
Previous Close
86.85
Open
86.77
Last Trade
20
@
86.89
Last Trade Time
Financial Volume
US$ 2,945,410
VWAP
86.6348
Average Volume (3m)
28,176
Shares Outstanding
461,340,700
Dividend Yield
1.07%
PE Ratio
2,199.54
Earnings Per Share (EPS)
1.94
Revenue
6.92B
Net Profit
893M

About Givaudan SA (PK)

Sector
Perfume,cosmetic,toilet Prep
Industry
Perfume,cosmetic,toilet Prep
Headquarters
Vernier, Che
Founded
-
Givaudan SA (PK) is listed in the Perfume,cosmetic,toilet Prep sector of the OTCMarkets with ticker GVDNY. The last closing price for Givaudan (PK) was US$86.85. Over the last year, Givaudan (PK) shares have traded in a share price range of US$ 75.5455 to US$ 110.315.

Givaudan (PK) currently has 461,340,700 shares in issue. The market capitalisation of Givaudan (PK) is US$40.07 billion. Givaudan (PK) has a price to earnings ratio (PE ratio) of 2199.54.

GVDNY Latest News

Givaudan Shares Climb After Results Beat Views

By Adria Calatayud Givaudan shares climbed after the Swiss chemicals company reported fourth-quarter sales and full-year profit figures that beat analysts' expectations. At 0825 GMT on...

Givaudan Net Profit Rises Despite Drop in Sales

By Adria Calatayud Givaudan reported a rise in net profit for last year, thanks to cost controls that allowed it to increase profitability and offset a drop in sales. Net profit for 2023 was 893...

Givaudan Continues to Increase Prices After Posting Lower 3Q Sales

By Andrea Figueras Givaudan reported a decline in sales for the third quarter in what it called a challenging environment in some of its markets and segments, and said it continues to implement...

Givaudan 1st Half Earnings Rose Despite Sales Slipping

By Cecilia Butini Givaudan said Thursday that its net profit and earnings per share rose in the first half of the year, though sales came in slightly lower. The Swiss flavor-and-fragrance company...

Givaudan First-Quarter Sales Fell Slightly Amid High Input Costs

By Pierre Bertrand Givaudan SA said Thursday that first-quarter sales declined slightly amid high input costs, but that it started the year with good momentum. The Swiss flavor-and-fragrance...

European Fragrance Stocks Fall After Regulators Probe Industry

By Pierre Bertrand Shares of European flavor and fragrance companies Givaudan SA and Symrise AG fell Wednesday after the companies were named by British and Swiss regulators investigating possible...

UK, Swiss Regulators Probe Fragrance Market

By Adria Calatayud Antitrust regulators in the U.K. and Switzerland said Wednesday that they have launched investigations into the fragrance industry, a day after the European Commission said it...

Givaudan Says 2022 Profit Rose Despite Challenges; Raises Dividend

By Giulia Petroni Givaudan SA on Wednesday said that profit rose in the full year with solid growth across segments and geographies, and raised its annual dividend. The Swiss flavor-and-fragrance...

Givaudan Shares Fall as 3Q Organic Sales Growth Misses Views

By Pierre Bertrand Shares in Givaudan SA fell Tuesday after the Swiss flavor-and-fragrance company reported third-quarter sales that came up short of expectations. At 0855 GMT, shares were down...

Givaudan 3Q Sales Rose; Increases Prices to Offset Higher Input Costs

By Pierre Bertrand Givaudan SA on Tuesday reported a rise in its third-quarter sales as it implements price increases to overcome higher input costs. Sales reached 1.81 billion Swiss francs ($1.81...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.35-1.5314804310888.1588.5985.84303987.81624155DR
4-2.56-2.8648164726989.3691.5985.83803388.64307908DR
12-15.88-15.4655239579102.68104.5784.612817689.92843887DR
26-8.34-8.7660290098895.14110.31584.612021793.94827746DR
527.529.4853683148379.28110.31575.54551932291.78396439DR
156-18.11-17.2624154037104.91110.31553.48993024873.4595471DR
26024.439.102564102662.4110.31553.48992721975.48906676DR

GVDNY - Frequently Asked Questions (FAQ)

What is the current Givaudan (PK) share price?
The current share price of Givaudan (PK) is US$ 86.80
How many Givaudan (PK) shares are in issue?
Givaudan (PK) has 461,340,700 shares in issue
What is the market cap of Givaudan (PK)?
The market capitalisation of Givaudan (PK) is USD 40.07B
What is the 1 year trading range for Givaudan (PK) share price?
Givaudan (PK) has traded in the range of US$ 75.5455 to US$ 110.315 during the past year
What is the PE ratio of Givaudan (PK)?
The price to earnings ratio of Givaudan (PK) is 2.2k
What is the cash to sales ratio of Givaudan (PK)?
The cash to sales ratio of Givaudan (PK) is 284.05
What is the reporting currency for Givaudan (PK)?
Givaudan (PK) reports financial results in CHF
What is the latest annual turnover for Givaudan (PK)?
The latest annual turnover of Givaudan (PK) is CHF 6.92B
What is the latest annual profit for Givaudan (PK)?
The latest annual profit of Givaudan (PK) is CHF 893M
What is the registered address of Givaudan (PK)?
The registered address for Givaudan (PK) is CHEMIN DE LA PARFUMERIE 5, VERNIER, 1214
What is the Givaudan (PK) website address?
The website address for Givaudan (PK) is www.givaudan.com
Which industry sector does Givaudan (PK) operate in?
Givaudan (PK) operates in the PERFUME,COSMETIC,TOILET PREP sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EGIOQEdgio Inc (CE)
US$ 0.01
(999,900.00%)
584
AAGRAfrican Agriculture Holdings Inc (CE)
US$ 0.008
(799,900.00%)
477
THCBFTHC Biomed International Limited (CE)
US$ 0.001
(99,900.00%)
100
AEORFAEON REIT Investment Corporation (PK)
US$ 796.08
(26,436.00%)
1
EFTReFFECTOR Therapeutics Inc (CE)
US$ 0.0002
(19,900.00%)
225
UFABQUnique Fabricating Inc (CE)
US$ 0.000001
(-99.98%)
102.53k
VICFFVice Health and Wellness Inc (CE)
US$ 0.000001
(-99.97%)
996
SAFSSafer Shot Inc (CE)
US$ 0.000001
(-99.93%)
2.54M
ERFBERF Wireless Inc (CE)
US$ 0.0001
(-99.89%)
99.77k
ARVLFArrival (CE)
US$ 0.0002
(-99.60%)
42.86k
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.0038
(52.00%)
608.97M
HMBLHUMBL Inc (PK)
US$ 0.0009
(0.00%)
546.25M
PHILPHI Group Inc (PK)
US$ 0.0003
(0.00%)
501.07M
CBIACanopus Biopharma Inc (PK)
US$ 0.0002
(100.00%)
281.95M
RDARRaadr Inc (PK)
US$ 0.00125
(-10.71%)
169.44M

Discussion

View Full Feed
Mr. Bill Mr. Bill 10 minutes ago
https://www.goodrx.com/well-being/sleep/how-to-sleep-with-sciatica
nowwhat2 nowwhat2 12 minutes ago
Could still just be climbing in sympathy w overall crypto mkt

Scathingly poor outlooks

https://www.youtube.com/watch?v=EOsjnOUAw14



https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg

WONDF
DonVance DonVance 14 minutes ago
This will hit 1k this year I believe now.
MSTR
georgejjl georgejjl 15 minutes ago
How many of the 7 million Alzheimer’s patients in the USA are projected to be treated with the MAB infusions during 2025???

How many people with Alzheimer’s in the USA are projected to be treated with donepezil (Aricept) or memantine during 2025???

The treatment used t
AVXL
Mr. Bill Mr. Bill 15 minutes ago
Stretches https://www.healthline.com/health/back-pain/sciatic-stretches#sitting-spinal-stretch
Graniteguy Graniteguy 16 minutes ago
Doc and Investor posters here tend to be negatively biased which you whole heartedly champion, especially "Doc" who's medical opinion is at best questionable, and incredibly biased, to fit a narrative of constant failure for Anavex's Blarcamesine. The fact that you pile onto their "steaming pile of
AVXL
BDEZ BDEZ 18 minutes ago
The Russes hit the jackpot?
BDEZ BDEZ 19 minutes ago
40% of homicides in the US take place in districts with a Soros-funded prosecutor.

Biden gave him a Medal Of Freedom.

https://x.com/EndWokeness/status/1875725808071012529
BDEZ BDEZ 20 minutes ago
Not good, thanks for sharing.
sand sand 27 minutes ago
Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.
SPY
mining101 mining101 27 minutes ago
Moving hard soon 
EFSH
mining101 mining101 28 minutes ago
Superb
MEGL
benz280c benz280c 35 minutes ago
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 42 minutes ago
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 43 minutes ago
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 46 minutes ago
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 52 minutes ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 52 minutes ago
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 57 minutes ago
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 59 minutes ago
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 60 minutes ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 1 hour ago
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT
nowwhat2 nowwhat2 1 hour ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
XRPUSD

Your Recent History

Delayed Upgrade Clock